Explore how CAR T-cell therapy is reshaping the battle against high-risk lymphoma, offering new hope as a frontline treatment based on the groundbreaking ZUMA-12 trial.
Discover how the tumor microenvironment creates resistance to Idelalisib in Marginal Zone Lymphoma and the groundbreaking research revealing new treatment approaches.